TGBA01AD

Summary

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[2][1][3] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.[4]

TGBA01AD
Clinical data
Other namesFKB01MD
Routes of
administration
By mouth
Pharmacokinetic data
Bioavailability17%[1]
Elimination half-life4 hours[1]
Chemical and physical data
3D model (JSmol)
  • Interactive image
  • OCC1OC(C(O)C1O)C2(O)NC=CC(=O)N2
  • InChI=1S/C9H14N2O6/c12-3-4-6(14)7(15)8(17-4)9(16)10-2-1-5(13)11-9/h1-2,4,6-8,10,12,14-16H,3H2,(H,11,13)
  • Key:QJTQVQQHNGHIKY-UHFFFAOYSA-N

See also edit

References edit

  1. ^ a b c "FKB01MD". Fabre-Kramer.
  2. ^ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595. S2CID 16286323.
  3. ^ Żmudzka E, Sałaciak K, Sapa J, Pytka K (October 2018). "Serotonin receptors in depression and anxiety: Insights from animal studies". Life Sciences. 210: 106–124. doi:10.1016/j.lfs.2018.08.050. PMID 30144453. S2CID 52090587.
  4. ^ "TGBA01AD". AdisInsight. Springer Nature Switzerland AG.